ASH 2018 | Reversible BTK inhibitor ARQ 531 for CLL and NHL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
ARQ 531 is a reversible inhibitor of wild type and C481S-mutant BTK. Here, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, tells us about the promising preliminary data from the Phase I dose escalation study (NCT03162536) across a variety of B-cell malignancies.
Get great new content delivered to your inboxSign up